Drug manufacturer Janssen, a Johnson & Johnson company, has notified 340B covered entities they are or might be owed refunds for overcharges on 14 widely used products during the first and second quarters of 2021.
Janssen asked the U.S. Health Resources and Services Administration (HRSA) to post the notice dated Sept. 17 on HRSA’s website. The products include eight NDCs for the type 2 diabetes medicine Invokamet, one NDC for the antipsychotic Risperdal, two NDCs for the immunosuppressive drug Simponi, and three NDC for the blood thinner Xarelto.
“Janssen will be communicating with and issuing refund adjustments through the wholesalers that submitted the original sale on behalf of the 340B covered entities,” the notice says. It includes an email address for entities to use “if you feel you have not received an
appropriate adjustment.”
